Navigate Your Brain Health

Amprion’s mission is to help people discover, understand, and benefit from quality brain aging.

Cracking the Code on Brain Health

We believe prevention is the secret to health and wellness. The key lies in accurate, early detection. For the first time in history, Amprion’s revolutionary discovery technology enables individuals to track all three known biomarkers associated with Alzheimer’s and Parkinson’s, as well as how they evolve as the brain ages. Our goal is to empower people with personal biometrics and collective knowledge that can help you and your doctor make informed choices for preventive brain care. Our job is to help you navigate quality brain aging.



Our body is made up of cells. And cells are made up of molecules of different types.
Of these types, proteins serve highly critical and diverse roles, both structural and functional. Encoded directly by our genes (DNA), proteins work by folding into particular, stable three-dimensional shapes.

Under circumstances related to genetics, environment, general health and brain aging, some proteins may misfold into non-functional or even toxic forms, known as prions (aka prion-proteins or prion-like particles). Prions can replicate autonomously within the body, and eventually take on a life of their own.

When the prion-proteins reach a critical mass in the brain, they trigger destruction of neurons in our brain, causing neurodegenerative diseases associated with the loss of higher brain functions. When this happens, it fundamentally changes who we are as people. Both our cognitive abilities and motor skills may be negatively affected. How we think, speak, act, and move becomes compromised… Our memories are blurred.

In short, we become a different person. Some of the commonly known prion-related neurodegenerative diseases include Alzheimer’s, Parkinson’s, and Creutzfeldt-Jakob disease.

Neurodegenerative diseases cause permanent, irreversible damage to the brain, which has very limited capacity to repair damaged neurons.


Prion-proteins have an alarming ability to replicate and spread throughout the brain and the body, by causing normal proteins in every cell to misfold and turn into prion-proteins, thereby multiplying exponentially. They operate in stealth, with incubation periods as long as several decades. A single prion-protein can replicate over time to fill the brain with its progeny and trigger massive neuronal loss.

To date, three different prion-proteins have been discovered to cause the most common neurodegenerative diseases including Alzheimer’s and Parkinson’s. They are:


In movie speak, prion-proteins are rogue agents, with the ability to grow an underground army and spread throughout. They are silent but deadly. Silent because they can exist under the radar for a long period of time, without being detected. Deadly due to their ability to “turn” other good guys to join them. In the end, they amass an über mobile army, ready to strike and takeover control when the time comes. And when they do, defeat ensues insidiously from within, as no one sees it coming. This is how prion-diseases work in simple terms.


As in many diseases, early detection is key to finding effective treatments and better yet: preventive care. Consider cancer and heart disease—thanks to recent breakthroughs in discovery tools, early detection in both cases has led to a dramatic increase in survival rates, as well as wellness prevention.

But this is not the case for neurodegenerative or prion-related diseases.

So why are prion-proteins so difficult to detect? For starters, they look in many ways like the normally folded proteins from which they are derived. Second, although the major damage observed is in the brain, prion-proteins are carried in the blood and can be sequestered in many different cells throughout the body. Finally, since a tiny amount of prion-proteins in the brain is all it takes to cause devastating effects, even the most sensitive detection methods currently available are often insufficient, prior to Amprion’s breakthrough discovery technology.

In short, the combination of its low levels of existence in the brain, sequestration in many cell types distant from the brain, and their stealth nature makes prion-proteins extremely challenging to detect, especially in the early stages.

Consequently, the lack of an accurate, early detection technology is the primary reason there is not even a single drug that can effectively treat Alzheimer’s and Parkinson’s, despite the pharmaceutical industry spending over $100 billion over the past 27 years in research and development.

And this problem is growing. Here are some key statistics:

  • The number of Americans with Alzheimer’s, Parkinson’s and related disorders is expected to grow to 20 million by 2050, with little current hope for effective treatment.
  • The medical/ hospice care for these Americans is estimated to cost $200,000/person/year or $4 trillion/year.
  • Countries, such as China, will have a much bigger problem with an estimated 100 million people with Alzheimer’s, Parkinson’s and related disorders by 2050 or $20 trillion/year.

So, early detection of prion-proteins is of critical importance—and an urgent global priority—in developing preventive brain care.

This brings us to Amprion and why we are here: We want to reinvent QUALITY BRAIN AGING.

For the first time in history, you and your doctor can monitor your brain health as it ages, using our proprietary prion-protein detection and analytical technologies.


Coming soon, we will offer two types of services:

C-PANEL is specifically for people who already show cognitive or motor symptoms suspected as being caused by Alzheimer’s, Parkinson’s or related neurodegenerative diseases. If clinical symptoms have already appeared, we recommend that your doctor send us a small sample of cerebrospinal fluid (CSF) since this gives the most accurate and sensitive measurement of prion-proteins in the brain. Your doctor can contact us here. We run diagnostic tests of all three (3) misfolded prion-proteins in your CSF sample.


B-PANEL is for EARLY DETECTION for people who do not have symptoms of neurodegenerative disease, but are at increased risk due to

  • Genetics
  • Repeated head injury
  • Family history
  • Other known or suspected risk factors

Since no symptoms are present, you and your doctor may choose to submit blood for analysis of all three prion proteins. This is less invasive, but also less sensitive and quantitative. The challenge is that the levels of prion proteins in the blood is 1% or less of that in the CSF. If prion-proteins are present in these fluids, Amprion’s test will find them, but detection and quantitation are less accurate than with CSF.

Our team is dedicated to Finding reliable, accurate scientific paths to solve life-threatening problems.


Russ Lebovitz, MD | PhD
CEO, CoFounder

Claudio Soto, PhD
CSO, CoFounder

Ben Vollrath, PhD

Luis Concha, PhD
Senior Scientist

Bret Holguin
Research Assistant

Christy Hui


Get in on the inside track and receive updates on brain health.

I'm a DoctorI'm a Neurologistother, please specify